EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
Emmaus Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026
- Market cap
- $6.03M
- P/E (TTM)
- –
- Dividend yield
- –
Emmaus Life Sciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endari - International [Member] | $3.39M | $3.57M | $3.18M | $2.67M | – | – | – | $6.96M | – | – | – | – | 21.8% |
| Other [Member] | $97.00K | $95.00K | $225.00K | $506.00K | $455.00K | $304.00K | $560.00K | $636.00K | $753.00K | $844.00K | $588.00K | $536.00K | 0.6% |
| Endari [Member] | – | – | – | – | $17.49M | $19.66M | $24.79M | $28.96M | $27.71M | $27.54M | $21.32M | $17.85M | – |
| Endari - U.S. [Member] | – | – | – | $13.48M | – | – | – | $22.00M | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Emmaus Life Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.